BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Daiichi Sankyo
Johnson and Johnson
Mallinckrodt
Queensland Health
Harvard Business School
Cipla
Julphar
Covington
Boehringer Ingelheim

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,469,182

« Back to Dashboard

Which drugs does patent 6,469,182 protect, and when does it expire?

Patent 6,469,182 protects HALAVEN and is included in one NDA.

This patent has thirty-eight patent family members in twenty-one countries.
Summary for Patent: 6,469,182
Title: Intermediates in the preparation of macrocyclic analogs
Abstract:Novel intermediates of the formula ##STR1## They are used in the preparation of macrocyclic analogs.
Inventor(s): Littlefield; Bruce A. (Andover, MA), Palme; Monica H. (San Jose, CA), Seletsky; Boris M. (Andover, MA), Towle; Murray J. (Auburn, NH), Yu; Melvin J. (Andover, MA), Zheng; Wanjun (Londonderry, NH)
Assignee: Eisai Co., Ltd. (Tokyo, JP)
Application Number:09/843,617
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,469,182

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Eisai Inc HALAVEN eribulin mesylate SOLUTION;INTRAVENOUS 201532-001 Nov 15, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER ➤ Subscribe
Eisai Inc HALAVEN eribulin mesylate SOLUTION;INTRAVENOUS 201532-001 Nov 15, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,469,182

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,097,648 Methods and compositions for use in treating cancer ➤ Subscribe
6,214,865 Macrocyclic analogs and methods of their use and preparation ➤ Subscribe
6,365,759 Intermediate compounds for preparing macrocylcic analogs ➤ Subscribe
8,148,554 Methods and compositions for use in treating cancer ➤ Subscribe
7,470,720 Methods and compositions for use in treating cancer ➤ Subscribe
6,653,341 Methods and compositions for use in treating cancer ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,469,182

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany 122011100031 ➤ Subscribe
Australia 2003284242 ➤ Subscribe
Germany 69943296 ➤ Subscribe
Brazil 9911326 ➤ Subscribe
Canada 2335300 ➤ Subscribe
Canada 2632433 ➤ Subscribe
Canada 2755266 ➤ Subscribe
China 1312804 ➤ Subscribe
China 1216051 ➤ Subscribe
Cyprus 1111516 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Accenture
Julphar
US Army
Teva
Colorcon
Covington
Cantor Fitzgerald
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot